Medtronic has reported late-breaking data from the randomised Evolut Low Risk Trial’s five-year outcomes of the Evolut ...

Medtronic says its Evolut TAVR shows strong valve performance and durable outcomes at 5 years in low-risk aortic stenosis ...

Patients with severe aortic stenosis had comparable rates of death or disabling stroke, but the lead investigator cautions ...

Medtronic, Abbott and Boston Scientific provided updates on their devices used in heart valve disease treatment at the event.

Here are the biggest stories out of ACC 2025: Five-year data from the Medtronic Evolut Low Risk Trial confirmed that its ...

Patients with severe aortic stenosis at low surgical risk who underwent supra-annular, self-expanding Evolut transcatheter ...

Medtronic (NYSE: MDT) stock was a fairly hot item as the trading week kicked off, with investors pushing the shares up by ...

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced late-breaking data on five-year outcomes from the Evolut Low Risk Trial. Data shows, versus surgery, the Evolut™ ...

Medtronic (MDT) announced late-breaking data on five-year outcomes from the Evolut Low Risk Trial. Data shows, versus surgery, the Evolut ...

Researchers found that at five years, patients with severe aortic stenosis who were treated with either TAVR or surgery had comparable rates of all-cause mortality or disabling stroke.

Among patients with severe aortic stenosis at low surgical risk, transcatheter aortic valve replacement and surgery conferred ...

1,414 patients were randomized, with 730 receiving TAVR with either a Medtronic Evolut R, PRO, or CoreValve™ and 684 undergoing surgery. "Results at five years support Evolut's supra-annular ...